Skip to main content

2-FMA Facts

Stimulant; Substituted amphetamine; Monoamine releasing agent

Description

2-FMA (2-fluoromethamphetamine) is a synthetic stimulant of the phenethylamine class. It releases dopamine and norepinephrine from nerve terminals into the synapse,[1][2] producing the focused wakefulness characteristic of amphetamine-type stimulants.

Subjective effects include focus enhancement, wakefulness, motivation, appetite suppression, and increased heart rate. The experience is utilitarian — sustained, directed attention without the rush or compulsive redosing of more recreational stimulants.[3]

Dependence potential is estimated as moderate by analogy to methamphetamine. Cardiovascular stress — elevated blood pressure, rapid heart rate, and vasoconstriction — is the primary physical danger, compounding with repeated use or high doses.[4][5]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 5 mgLight5 – 15 mgCommon15 – 30 mgStrong30 – 50 mgHeavy50+ mg

Starts in 30 – 60 minLasts 7 – 9 hoursAfter-effects 4 – 12 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Moderate
Physical dependence
Moderate
Psychological dependence
Moderate
Withdrawal
Moderate
Compulsive redosing
Low

Tolerance

Builds
Moderate
Fully resets after
10.5 days
Carries over to
amphetamine; methamphetamine; other dopaminergic stimulants; other fluorinated amphetamines

Effectslikely at a common dose

Body
Pupil dilation; Vasoconstriction; Appetite suppression; Stimulation; Wakefulness; Insomnia; +24 possible, including Temperature dysregulation, Excessive sweating, Dehydration sensation
Thinking
none likely · 21 possible, including Compulsive redosing urge
Feeling
none likely · 8 possible, including Anxiety, Depression, Anhedonia
Self
none likely · 10 possible, including Ego inflation, Craving, Compulsive repetitive behavior
Awareness
One-pointedness (ekaggata); Sustained attention (vicara); +1 possible

Who shouldn't take it

Absolute
Severe cardiovascular disease; MAO inhibitors; Concurrent tramadol use
Relative
Seizure disorders; Psychotic disorders; Hyperthyroidism; Pregnancy and lactation; Narrow-angle glaucoma

Combinations61 recorded

Lethal (2)
MAOIs; Tramadol
Dangerous (28)
Alpha-2 adrenergic receptor antagonist; Anticholinergics; Caffeine; Ephedrine, Pseudoephedrine; GHB, Baclofen; Local anesthetics; MDMA, Amphetamines; MDMA, MDA; NDRIs (Wellbutrin); NRIs; Opioids; SNRIs; SSRIs; Stimulants; 5-HTP, Tryptophan; Antipsychotics; Buspirone; Dopamine agonists; DXM; GHB, GBL; Ibogaine; Ketamine, DXM, PCP; Lithium; NSAIDs; and 4 more, see full page
Caution (28)
See full page: psychedex.org/substances/2-fma
Not graded (3)
Not listed never means safe.

Seek help immediately if

  • Chest pain; racing, pounding, or irregular heartbeat
  • Very high body temperature; heavy sweating; hot, flushed skin
  • Severe agitation, paranoia, panic, or confusion
  • Severe headache; muscle rigidity or twitching
  • Seizures
  • Signs of stroke — face drooping, one-sided weakness, slurred speech
  • Difficulty breathing; collapse or unconsciousness

What to do

  1. Call emergency services for chest pain, overheating, seizure, or unresponsiveness
  2. Move them to a cool, quiet place and reduce stimulation
  3. Cool the body — remove excess clothing, apply cool damp cloths, fan them
  4. Keep them calm; reassure — panic worsens the cardiovascular strain
  5. If seizing, protect from injury (don't restrain); recovery position afterward
  6. Monitor breathing and be ready to give rescue breaths / CPR

Most stimulant overdoses settle with cooling, a calm environment, and time. The medical danger is hyperthermia, cardiac events (arrhythmia, heart attack, stroke), and seizures — get help immediately if any appear.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1.a1 · Not medical advice

References

  1. [1]
    ^Simmler LD, Liechti ME (2018) Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_113
  2. [2]
    ^Luethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects — Archives of Toxicology doi:10.1007/s00204-020-02693-7
  3. [3]
    ^Anchondo O, Shetty RA, Gatch MB (2025) Locomotor and discriminative stimulus effects of fluorinated analogs of amphetamine and methamphetamine in mice and rats — Journal of Pharmacology and Experimental Therapeutics doi:10.1016/j.jpet.2025.103617
  4. [4]
    ^Annawald K, Streckfuss-Bomeke K, Meyer T (2024) Methamphetamine-induced cardiotoxicity: in search of protective transcriptional mechanisms — Herz doi:10.1007/s00059-024-05279-6
  5. [5]
    ^Schep LJ, Slaughter RJ, Beasley DM (2010) The clinical toxicology of metamfetamine — Clinical Toxicology doi:10.3109/15563650.2010.516752
Print version
Report an issue